INDGN - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 3.1
| Stock Code | INDGN | Market Cap | 10,722 Cr. | Current Price | 446 ₹ | High / Low | 633 ₹ |
| Stock P/E | 55.3 | Book Value | 81.6 ₹ | Dividend Yield | 0.45 % | ROCE | 16.6 % |
| ROE | 12.6 % | Face Value | 2.00 ₹ | DMA 50 | 478 ₹ | DMA 200 | 524 ₹ |
| Chg in FII Hold | 0.18 % | Chg in DII Hold | 1.11 % | PAT Qtr | 34.8 Cr. | PAT Prev Qtr | 59.9 Cr. |
| RSI | 40.6 | MACD | -12.7 | Volume | 2,85,999 | Avg Vol 1Wk | 10,02,179 |
| Low price | 423 ₹ | High price | 633 ₹ | PEG Ratio | 5.30 | Debt to equity | 0.03 |
| 52w Index | 10.8 % | Qtr Profit Var | -30.3 % | EPS | 8.08 ₹ | Industry PE | 49.5 |
📊 Indegene (INDGN) shows moderate potential for long-term investment. While the company has strong ROCE (16.6%) and decent ROE (12.6%), the high P/E (55.3 vs industry 49.5) and very high PEG ratio (5.30) suggest overvaluation. Profitability has weakened (PAT down 30.3% QoQ), and technical indicators show bearish momentum. Low debt (0.03) and institutional inflows provide stability, but valuations remain stretched.
💰 Ideal Entry Price Zone
Considering book value (81.6 ₹), DMA levels (478–524 ₹), and current weakness, the ideal entry zone lies between 430 ₹ – 450 ₹
📈 Exit Strategy / Holding Period
If already holding, investors should maintain a 2–3 year horizon, exiting near 600–620 ₹
✅ Positive
- Strong ROCE (16.6%) and ROE (12.6%)
- Debt-free balance sheet (Debt-to-equity 0.03)
- DII holdings increased (+1.11%), showing domestic confidence
- EPS of 8.08 ₹ supports earnings base
⚠️ Limitation
- High P/E of 55.3 vs industry 49.5
- PEG ratio of 5.30 indicates overvaluation relative to growth
- Quarterly profit decline (-30.3%)
- Low dividend yield (0.45%)
📰 Company Negative News
- Quarterly PAT dropped significantly (59.9 Cr → 34.8 Cr)
- Technical weakness: RSI near 40, MACD negative
🌟 Company Positive News
- Institutional confidence with increased DII holdings
- FII holdings also slightly improved (+0.18%)
🏦 Industry
- Industry P/E at 49.5, INDGN trades at a premium
- Healthcare and life sciences sector supported by digital transformation and outsourcing demand
🔎 Conclusion
Indegene offers moderate investment potential with strong efficiency metrics and low debt, but current valuations are stretched and profitability has weakened. Entry near 430–450 ₹ is ideal, with a holding period of 2–3 years. Investors should monitor earnings growth closely, as returns depend mainly on capital appreciation rather than dividends.